DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

Phase 2

Conditions: Gastric Cancer
Metastasis

Interventions: Drug: Apatinib Mesylate
Drug: Camrelizumab

First Posted Date: 2021-10-27

Last Posted Date: 2021-10-27

Lead Sponsor: Fudan University

Target Recruit Count: 102

Registration Number: NCT05095636

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC (ECTOP-1010)

Recruiting

Conditions: Non-small Cell Lung Cancer
Carcinoma

Interventions: Procedure: pulmonary lobectomy

First Posted Date: 2021-10-26

Last Posted Date: 2023-07-20

Lead Sponsor: Fudan University

Target Recruit Count: 500

Registration Number: NCT05094882

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China

A Cohort of Molecular Characteristics and Prognosis of Colorectal Cancer

Conditions: Colorectal Cancer
Surgery

First Posted Date: 2021-10-21

Last Posted Date: 2021-10-21

Lead Sponsor: Fudan University

Target Recruit Count: 15000

Registration Number: NCT05086601

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Phase 3

Recruiting

Conditions: Stage II Colorectal Cancer
Stage III Colorectal Cancer

Interventions: Drug: Thymosin Alpha1

First Posted Date: 2021-10-21

Last Posted Date: 2021-10-21

Lead Sponsor: Fudan University

Target Recruit Count: 2500

Registration Number: NCT05086614

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

Phase 2

Recruiting

Conditions: Estrogen Receptor-positive Breast Cancer
HER2-positive Breast Cancer

Interventions: Drug: Palbociclib
Drug: trastuzumab
Drug: pyrotinib
Drug: fulvestrant

First Posted Date: 2021-10-13

Last Posted Date: 2021-10-13

Lead Sponsor: Fudan University

Target Recruit Count: 37

Registration Number: NCT05076695

Locations: 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China

Reverse Triple Negative Immune Resistant Breast Cancer

Phase 2

Recruiting

Conditions: Triple-negative Breast Cancer

Interventions: Drug: anti-PD-1 antibody and chemotherapy
Drug: Choline
Drug: Sodium Cromoglicate
Drug: Efavirenz

First Posted Date: 2021-10-13

Last Posted Date: 2022-10-03

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT05076682

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant

Phase 4

Conditions: POST LIVER TRANSPLANT
HBV

Interventions: Drug: Tenofovir Alafenamide 25 MG

First Posted Date: 2021-09-30

Last Posted Date: 2021-09-30

Lead Sponsor: Fudan University

Target Recruit Count: 150

Registration Number: NCT05063071

Locations: 🇨🇳
Zhongshan hospital, Fudan University, Shanghai, Shanghai, China

Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer

Phase 3

Recruiting

Conditions: Radiotherapy; Complications
Effect of Radiation Therapy
Breast Cancer

Interventions: Radiation: Medial supraclavicular lymph node radiotherapy
Radiation: Entire supraclavicular lymph node radiotherapy

First Posted Date: 2021-09-28

Last Posted Date: 2021-10-25

Lead Sponsor: Fudan University

Target Recruit Count: 1650

Registration Number: NCT05059379

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis

Phase 2

Recruiting

Conditions: Liver Metastases
Colorectal Cancer Metastatic

Interventions: Drug: Sintilimab
Drug: Regorafenib
Combination Product: US/CT-guided Percutaneous Cryoablation

First Posted Date: 2021-09-27

Last Posted Date: 2025-02-27

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT05057052

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma

Phase 2

Recruiting

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Drug: Tislelizumab
Drug: lenvatinib
Combination Product: US/CT-guided Percutaneous Cryoablation

First Posted Date: 2021-09-27

Last Posted Date: 2025-02-27

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT05057845

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy